Dermira Inc (DERM) : Aisling Capital scooped up 150,000 additional shares in Dermira Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 970,823 shares of Dermira Inc which is valued at $27 Million.Dermira Inc makes up approximately 6.12% of Aisling Capital’s portfolio.
Other Hedge Funds, Including , Sabby Management added DERM to its portfolio by purchasing 122,600 company shares during the most recent quarter which is valued at $3.4 Million. Dermira Inc makes up approx 1.18% of Sabby Management’s portfolio. Mufg Americas Holdings Corp added DERM to its portfolio by purchasing 110 company shares during the most recent quarter which is valued at $3,058.Teachers Advisors Inc boosted its stake in DERM in the latest quarter, The investment management firm added 2,278 additional shares and now holds a total of 123,531 shares of Dermira Inc which is valued at $2.9 Million. Dermira Inc makes up approx 0.01% of Teachers Advisors Inc’s portfolio.Swiss National Bank boosted its stake in DERM in the latest quarter, The investment management firm added 8,200 additional shares and now holds a total of 23,600 shares of Dermira Inc which is valued at $556,960.
Dermira Inc closed down -0.03 points or -0.10% at $30.9 with 2,05,238 shares getting traded on Wednesday. Post opening the session at $31.01, the shares hit an intraday low of $30.29 and an intraday high of $31.86 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Needham on May 11, 2016 to “Buy”, Firm has raised the Price Target to $ 42 from a previous price target of $38 .
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.